The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
REGULATORY
Planning to Resume “Public-Private Dialog” by Year-End: EAD Director Kamata
Mitsuaki Kamata, Director of the Health Policy Bureau’s Economic Affairs Division (EAD) revealed at a symposium held by IMS Japan on October 26 that the EAD is adjusting the schedule to resume the government-private sector dialogue, which was postponed due…
To read the full story
REGULATORY
- Japan’s FY2025 Draft Budget Clears Lower House
March 5, 2025
- Three-Party Talks to Be Held on Health Coverage of OTC-Like Drugs: Minister
March 4, 2025
- No Prior Talks with US Drug Makers for Deferred PMP Price Cuts: Health Minister
March 3, 2025
- Japan Grants Orphan Tags to Atrasentan, Efzimfotase, and Lots More
March 3, 2025
- Japan to Revisit Copay Cap Hike Plan for 2026 and Beyond: Ishiba
March 3, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…